Brain Barriers' Paths, Leaks, and Neurodegeneration {#S1}
===================================================

The term neurodegenerative describes a progressive deterioration of the central nervous system (CNS) that is frequently associated with abnormal accumulation of proteins. Importantly, neurofibrillary tau-protein tangles are not only a major sign of Alzheimer's disease (AD) but are reported in temporal lobe epilepsy and post-traumatic encephalopathies ([@B157]). Among the emerging disease mechanisms, a peripheral--CNS pathological interplay is proposed to contribute to the neurodegenerative process ([@B90]; [@B39]; [@B41]; [@B121]; [@B126]; [@B73]). Accordingly, harmful events occurring at the cerebrovascular interface are being examined as key determinants partaking to or even preceding neurodegeneration ([@B184]; [@B108]; [@B156]). At the cerebrovasculature, specialized endothelial cells, mural cells, and astroglia constructs ([@B1]; [@B42]; [@B156]) provide physical and biological properties governing the homeostatic--immune interactions between peripheral blood cells, or molecules, and brain neuroglia. The physiological parenchymal milieu composition ensures a healthy neuronal transmission, attainable because of the tightness of the blood--brain barrier (BBB; [@B183]; [@B42]; [@B108]). At the pial arterial and venous level, the cerebrovasculature is permissive to blood cells or molecules, while it becomes impermeable at the arteriole--capillary level where barriers' properties are fully established ([@B1]). BBB vessels also contribute to cerebrospinal and interstitial fluid movements and the elimination of waste products from the interstitial and perivascular spaces ([@B111]).

It is increasingly recognized that a BBB pathological imprint can provoke a brain pro-inflammatory disequilibrium sufficient to modify neuronal activity in the long term ([@B86], [@B90]; [@B108]). Vascular-dependent mechanisms of neurodegeneration can rapidly elicit as a consequence of peripheral infections, head trauma, ischemic stroke, or status epilepticus ([Figure 1](#F1){ref-type="fig"}; [@B108]; [@B156]). These are risk factors for the development of long-term neurodegenerative sequelae and encephalopathies (e.g., post-concussion or head trauma-related chronic traumatic encephalopathy, CTE), cerebral amyloid angiopathy (CAA), AD, and epilepsy. Under conditions of increased BBB permeability, an aberrant bidirectional exchange between the neurovascular unit and the peripheral blood occurs, compounding to neurodegenerative modifications ([Figure 1](#F1){ref-type="fig"}; [@B90]; [@B39]; [@B41]; [@B121]; [@B126]; [@B73]). Completing a vicious cycle, beta-amyloid deposition in the brain can provoke capillaries dysfunction ([@B163]; [@B177]; [@B52]; [@B31], [@B32]; [@B112]). As an example, reactive oxygen species and endothelin-1 production were proposed to elicit vasoconstriction at pericyte locations ([@B112]). A question remains regarding whether the endothelin-1 mechanism can directly drive neurodegeneration.

![The periphery--brain interplay and CNS disease: the neurovascular pathological imprint. **(A)** Proper peripheral--brain segregation under healthy conditions (neurovascular unit, NVU; *blue lines*). **(B)** Pathological insult(s) elicited in the periphery or in the brain (traumatic brain injury, TBI; status epilepticus, SE) converge to NVU damage (e.g., BBB permeability) and neuro-inflammation, leading to temporary or prolonged loss of brain homeostatic control (**B1**, *red arrows*). **(B2)** Under conditions of BBB permeability, concentration gradients favor brain-derived proteins to extravasate into the peripheral blood. Under this condition, a peripheral auto-immune reaction may mount leading to the production of autoantibodies, possibly re-entering into the CNS if BBB damage endures **(B3)**.](fnagi-12-00003-g001){#F1}

Autoantibodies and Neurodegeneration: Bad, Good, or Nil? {#S2}
========================================================

The communication between the peripheral blood and the brain occurs at preferential cerebrovascular sites ([@B184]; [@B111]), e.g., at post-capillary venules or pial vessels, and by a system of lymphatic vessels draining the cerebrospinal and interstitial fluids to cervical lymph nodes ([@B10]; [@B79], [@B81], [@B80]). At the intravascular level, moving leukocytes shape a peripheral--brain immune dialog where endothelium activation or permeability, perivascular immune cell homing, and brain entry of immune soluble factors prompt and sustain neuroglia inflammation \[[Figure 1](#F1){ref-type="fig"}; see [@B39] and [@B131] for fundamental aspects of endothelial--leukocyte adhesion\]. The implication of the cerebrovascular interface to innate and adaptive modalities of immunity is central ([@B143]; [@B152]). Adaptive immunity to the brain requires T- and B-cell stimulation at extra-CNS lymphatic organs and by professional antigen-presenting cells ([@B54]), thus implying the existence of a peripheral--brain immune dialog, e.g., via the CNS vascular and lymphatic routes ([@B111]).

A question exists on whether neurodegeneration may result from autoimmune-like processes ([Table 1](#T1){ref-type="table"}). Contingent to a prolonged or recurrent BBB permeability, specific antigens could exit the brain to reach the bloodstream, mounting a peripheral humoral response. Newly formed brain-directed autoantibodies could be neuropathological upon their entry into the brain across a continuously damaged BBB ([@B76]). Importantly, autoantibodies and autoreactive T cells were reported in the cerebrospinal fluid (CSF), sera, as well as in the brain of AD patients and experimental models of disease ([Table 1](#T1){ref-type="table"}; [@B68]; [@B176]). Anti-Aβ antibodies (Ig type G) correlated with scores of dementia ([@B175]). Intrathecal antibodies against tau filaments were reported in AD patients ([@B104]) and were proposed as contributors of disease progression ([@B14]). Anti-tau autoantibodies are not specific to AD as they are increased in patients suffering from other neurodegenerative diseases, e.g., multiple sclerosis ([@B40]).

###### 

Autoantibodies reported in neurodegenerative disease and post-TBI.

  Autoantibodies                 Neuro- pathology   Stage                                                                        Model investigated   Sample               Observed effects                                                                                     Isotype           References
  ------------------------------ ------------------ ---------------------------------------------------------------------------- -------------------- -------------------- ---------------------------------------------------------------------------------------------------- ----------------- ---------------------------------------------------------------------------------------------
  Anti-neuronal antibody         TBI                Moderate acute TBI                                                           AM                   Serum                --                                                                                                   IgG               [@B136]
  Anti-neurofilament             AD                 Moderate forms of AD                                                         H                    Serum, CSF           --                                                                                                   IgG. IgM          [@B14]
  Anti-Aβ                        AD                 Mild to severe forms of AD, early and late onset                             H                    Serum, CSF           Suggested to favor Aβ clearance; correlation with global scores of dementia                          IgG {IgG2}, Nab   [@B105]; [@B15]; [@B29]; [@B143]; [@B9]; [@B61]; [@B137]; [@B152]; [@B103]; [@B109]
  Anti-Tau                       AD, TBI            Mid to severe forms of AD                                                    H                    Serum, CSF, tissue   Levels correlated with reduced Plaque burden                                                         IgG, Nab          [@B36]; [@B174]; [@B104]; [@B18]; [@B135]; [@B46]; [@B47]; [@B19]; [@B175]; [@B84]; [@B128]
  Anti-AMPA receptor             AD, TBI            Moderate to severe AD Mild and repetitive concussion in children             H                    Serum                Levels increased in moderate and severe dementia                                                     --                [@B45]
  Anti-NMDA receptor             AD, TBI            Moderate to severe AD and dementia, mild and repetitive concussion           H                    Serum                Relationship between autoantibody titers and aging                                                   IgG               [@B45]; [@B20]
  Anti-acetyl choline receptor   TBI                TBI to different severity in children                                        H                    Serum                Levels correlate with trauma severity                                                                --                [@B153]
  Anti-Dopamine                  AD                 Mid to severe forms of AD                                                    H                    Serum                Match to moderate to severe dementia progression                                                     IgG               [@B105]; [@B46]
  Anti-5-HT                      AD                 Mild to severe forms of AD                                                   H                    Serum                Levels increased during mild dementia                                                                --                [@B105]
  Anti-GFAP                      AD, TBI            Pre-senile and senile forms of AD, senile vascular dementia                  H                    Serum                Relationship between autoantibody titers and aging suggested as a maker of BBB damage                IgG               [@B158]; [@B46]
  Anti-S100β                     AD, TBI            Mild to severe AD, senile vascular dementia, repealed acute sub-concussion   H                    Serum                Match to moderate--severe dementia progression; relationship between autoantibody titers and aging   IgG               [@B96]; [@B46]; [@B87]
  Anti-microglia                 AD                 Mid to severe forms of AD                                                    H                    CSF                  --                                                                                                   IgG               [@B95]
  Anti-phospholipid              AD, TBI            Mid cognitive impairment to advanced AD, severe TBI                          H                    Serum, CSF           Levels correlate with erythrocytes and proteins in CSF                                               IgG               [@B93]; [@B94]
  Anti-ceramide                  AD                 Chronic pathology in TG mice                                                 AM                   Serum                Levels correlate with plaque formation                                                               IgG               [@B33]
  Anti-RAGE                      AD                 Mild cognitive impairment to severe AD                                       H                    Serum                Relationship with anti-Aβ levels; correlation with global scores of dementia                         IgG               [@B104]; [@B175]
  Anti-ATP synthase              AD                 Mild to severe AD                                                            H                    Serum                Induced the inhibition of ATP synthesis                                                              IgG               [@B167]
  Anti-pituitary                 TBI                Mild to severe TBI, acute and long-term                                      H                    Serum                Association between antibody positivity and hypopituitarism due to head trauma                       IgG               [@B160]; [@B159]; [@B119]
  Anti-adrenergic receptors      AD                 Mild to moderate dementia                                                    H                    Serum                Suggested contribution to vascular lesions and increased plaque formation                            IgG               [@B56]

AM, data derives from animal models only.

The significance of peripheral autoantibodies as biomarkers of neurodegenerative conditions also remains to be established. Autoantibodies against the glutamate receptor *N*-methyl-[D]{.smallcaps}-aspartate receptor (NMDAR) were detected in plasma of AD patients ([@B30]). Levels of antibodies were shown to correlate with clinical severity, as patients affected by moderate and severe dementia presented a twofold autoantibody increase compared with patients suffering from mild dementia ([@B30]). The presence of autoantibodies against 5-HT was also reported ([@B105]), with levels increasing during the mild phase of the disease, subsequently reaching a plateau ([@B105]). Similar findings were reported for autoantibodies directed against the receptor for advanced glycation end products ([@B175]). In a transgenic model of AD, autoantibodies against the sphingolipid ceramide correlated with amyloid plaque increase ([@B125]; [@B33]). Autoantibodies against ATP synthase ([@B167]), α(1)-adrenergic, and the β(2)-adrenergic receptors were also reported ([@B56]). Autoantibodies against the α(1)-adrenergic and the β(2)-adrenergic receptors may contribute to vascular lesions and increased plaque formation in AD patients ([@B56]).

Importantly, not all autoantibodies are harmful. Brain-reactive natural autoantibodies (NAbs) are protective ([@B19]; [@B58]; [@B34]; [@B12]). NAbs are mostly IgM and are spontaneously produced. NAbs are polyreactive with low affinity for self-antigens ([@B22]). Physiologically, NAbs facilitate phagocytosis of apoptotic cells, inhibit inflammatory pathways, and have a role in maintaining immune tolerance ([@B38]). NAbs to Aβ can inhibit plaque aggregation, block Aβ toxicity, and catalyze Aβ clearance ([@B78]). Immunotherapies using specific, or aspecific, autoantibodies were tested. Bapineuzumab is the humanized form of a monoclonal anti-Aβ antibody targeting the N-terminus of Aβ. In phase II trials, Bapineuzumab administration reduced Aβ plaques in AD brains ([@B138]; [@B134]) and was associated with decreased total and phospho-tau levels in the CSF ([@B11]). Bapineuzumab was, however, discontinued after a phase III trial and showed no beneficial effects on cognitive or functional outcomes ([@B165], [@B166]). Aducanumab (BIIB037) is a human monoclonal antibody selectively targeting aggregated Aβ (oligomers and fibrils) ([@B145]). An Aducanumab phase III trial was terminated as endpoints were not meet. The analysis of a larger data set is ongoing. Tau immunotherapies are also being developed, attenuating or preventing functional impairment in experimental models, as reviewed in [@B148].

Autoantibodies and Post-Traumatic Encephalopathy {#S3}
================================================

Resulting from repeated head trauma and BBB damage, chronic traumatic encephalopathy (CTE) presents with accumulation of neurofibrillary tau-protein tangles. In TBI subjects, blood and CSF autoantibodies were suggested as etiological components or as possible biomarkers of neurodegeneration ([@B129]; [@B63]; [Table 1](#T1){ref-type="table"}). Anti-glial fibrillary acidic protein (GFAP) fragments were found in the sera of TBI patients ([@B179]). Serum autoantibodies against S100B were reported in American football players when repeated sub-concussive events were associated with BBB damage ([@B87]). Autoantibodies against the neuronal α7-subunit of the acetylcholine receptor ([@B153]) as well as AMPA and NMDA receptors ([@B45]) were detected in TBI subjects, while IgG autoantibodies to neurons and basal lamina were reported in rat serum following experimental head trauma ([@B136]). Autoantibodies to the pituitary gland were reported in TBI subjects 3 years after the trauma ([@B160], [@B159]). Damage to the pituitary gland is distinctive of the TBI pathology with 20--50% of patients showing some degrees of pituitary dysfunction, which affects growth hormone production ([@B4]; [@B161]). An association between anti-pituitary autoantibodies and pituitary dysfunction was reported in patients suffering from mild TBI, including repetitive concussions ([@B159]).

Autoreactive antibodies have been proposed for the treatment of TBI sequelae. The presence of hyper-phosphorylated tau accumulating in neurofibrillary tangles is a characteristic of CTE ([@B115]). Even if phospho-tau is detectable only at low levels acutely after TBI ([@B151]; [@B16]; [@B43]; [@B85]), a specific form of phospho-tau can be produced in response to TBI (*cis* P-tau) ([@B64]). This protein spreads throughout the brain, harming cells and leading to post-traumatic neurodegeneration and dementia. In two animal models of TBI, administration of a monoclonal antibody discriminating between the *cis* and the *trans* forms of the protein and blocking *cis* P-tau prevented the onset of tauopathy and cortical atrophy. These accumulating evidence supports the possible involvement of autoantibodies in post-TBI neurodegenerative conditions, perhaps providing new disease biomarkers and therapeutic entry points.

The Gut--Brain Axis and Neurodegeneration: Is There a Barrier Implication? {#S4}
==========================================================================

Here, we discuss a specific framework where alterations of the gut microbiota (GM) could impact BBB permeability, promote neuro-inflammation, and favor neurodegenerative modifications ([Figure 2](#F2){ref-type="fig"}; [@B17]; [@B24]; [@B120]; [@B172]). Bacteria, viruses, parasites, and non-pathogenic fungi constitute the intestinal microbiota. These complex communities of microbes colonizing the gastrointestinal tract are major players in health. Modern life and diets have progressively induced changes in the composition of the GM, perhaps for the worse, as this can contribute to chronic illnesses ([@B82]; [@B106]; [@B71]; [@B146]; [@B28]; [@B117]; [@B133]). Intestinal microbes can influence brain function through a continuous dialog involving the immune, the vascular, and the nervous systems ([Figure 2](#F2){ref-type="fig"}; [@B142]; [@B26]; [@B21]; [@B28]). Modifications in the composition of the GM was reported in brain disorders, such as autism ([@B2]; [@B55]), depression ([@B59]; [@B180]), Parkinson's disease ([@B140]; [@B139]), and AD ([@B23]; [@B171]; [@B182]). Intriguingly, the extent of the amyloid pathology in AD mice appears to be dependent of the microbial status, which is specific to the animal housing facility. APP/PS1 mice bred in a germ-free facility displays decreased amyloid plaque number compared to mice housed in non-germ-free conditions ([@B48]). Moreover, the administration of broad-spectrum, combinatorial antibiotics to APP/PS1 mice, either during the peri-natal or the adult stage, reduced brain Aβ deposition ([@B100], [@B99]).

![Gut--brain axis: communication routes and physiological barriers. A double, peripheral, and brain homeostatic control is performed by the intestinal--epithelial and blood--brain barriers under healthy conditions. Rupture of one barrier (e.g., gut) may impact the other (e.g., brain), with the blood stream and the immune system being the facilitators or the arbitrators of the pathological spread and neuro-inflammation.](fnagi-12-00003-g002){#F2}

Existing reports support the hypothesis of a possible infectious origin of AD. Aβ was proposed as an antimicrobial peptide ([@B154]; [@B101]) responding to pathogens ([@B70]; [@B37]). Infectious agents, such as *Chlamydia pneumonia*, *Proprionibacterium acne*, *Helicobacter pylori*, *Porphyromonas gingivalis*, or *spirochetes*, are associated with AD ([@B65]; [@B13]; [@B67]; [@B97]; [@B124]). A microbial hypothesis is supported by evidence describing the presence of viruses, such as Herpes simplex virus type I, in the brains of AD patients ([@B77]; [@B6]; [@B53]).

Within the complex interplay between the gut microbiome and the CNS, a role for brain barriers and neuroinflammation is becoming important ([@B17]; [@B24]; [@B120]; [@B172]). The impact of the gut microbiome composition on CNS health was reported ([@B7]; [@B25]; [@B147]; [@B170]). Recent work demonstrated that GM composition controls BBB development and permeability in mice ([@B17]). In AD, increased gut permeability due to GM dysbiosis was reported during prolonged stress. In this condition, molecules that are normally secluded in the intestine, e.g., inflammatory mediators, bacteria, or bacterial-derived agents, could leak out and reach the peripheral blood. Bacterial DNA, metabolites, or proteins circulating in the blood stream could, in turn, modify BBB permeability ([@B17]; [@B106]; [@B71]; [@B24]; [@B120]; [@B172]). Existing reports indicated bacterial DNA in human blood with a possibility for brain access ([@B75]; [@B118]; [@B141]). Brain entry of *P. gingivalis*, a bacterium associated with periodontal disease, has been described ([@B35]). Gingipain inhibitors reduced the bacterial load and the bacteria-induced neuro-inflammation in a mouse model ([@B35]). Among Spirochetes, *Borrelia burgdorferi* is a strain associated with Lyme dementia that could enter the brain. In humans, this specific strain can form biofilms similar to senile plaques. Aβ and bacterial DNA appear as important constituents of these biofilms, suggesting that amyloid plaques may originate in association with or from the spirochetal colonies ([@B5]; [@B98]).

These examples highlight the need of tightly regulated intestinal and brain barriers ([@B130]). In AD, a dysbiotic GM may enhance gut permeability and alter BBB integrity, allowing the access of infectious agents or associated molecules into the brain ([@B91]). Significantly, intestinal and brain barriers are reactive to analogous pro-inflammatory triggers. Circulating inflammatory cytokines IL-17, interferon-gamma (IFN-γ), and the small intestine epithelium protein zonulin can damage the intestinal--epithelia and BBBs ([@B130]).

Gut Microbiota and Autoantibodies: Initial Clues {#S5}
================================================

Hypotheses linking modifications of the GM and production of autoantibodies are emerging ([@B123]). Some evidence supports the concept that specific dietary components may affect B-cell maturation and activity, ultimately leading to the formation of autoantibodies ([@B123]). Obesity was associated with a systemic pro-inflammatory state, characterized by changes in the frequency of B-cell subpopulation \[e.g., reduction of the anti-inflammatory IL-10^+^ regulatory B cell ([@B110])\] and by an increase in autoantibody levels ([@B66]). Diets rich in polyunsaturated fatty acid are associated with the suppression of pro-inflammatory responses and a reduction of circulating autoantibodies ([@B122]; [@B164]). Dietary components impact the composition of the gastrointestinal bacterial populations: consumption of prebiotics increases the intestinal levels of *Bifidobacterium* and *Lactobacillus* ([@B149]), with a possible link to B-cell differentiation, maturation, and activation ([@B116]). Diet can impact autoantibody production, directly by promoting pro-inflammatory conditions and indirectly by altering the GM. In experimental autoimmune encephalomyelitis (EAE) it was demonstrated that the commensal microbiota composition is a pivotal factor for disease development ([@B74]) and that modifying the GM impacts the levels of T and B cells or the levels of circulating autoantibodies ([@B113], [@B114]).

BBB Repairing Pharmacology: Available Options {#S6}
=============================================

The multi-level implication of BBB damage in neurodegenerative disorders has prompted the quest for pharmacological repairing strategies, either directed at the endothelium or by indirect targeting of the cellular players of peripheral and neuro-inflammation. Currently tested drugs are either repurposed or new ([Table 2](#T2){ref-type="table"}). Examples include losartan, an anti-hypertensive molecule acting as an angiotensin II antagonist. Losartan was shown to reduce BBB permeability in a rat model of hypertension ([@B69]; [@B57]) and following pilocarpine-induced status epilepticus ([@B50]). BBB protection by losartan depends on angiotensin receptor type 1 (AT1) blockade. Another drug is rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR) pathway. Rapamycin improved cerebrovascular and cognitive function in a mouse model of AD ([@B168]). Inhibition of mTOR preserved BBB integrity through the upregulation of tight junction proteins and downregulation of matrix metalloproteinase-9. A third option is anakinra, which is the recombinant form of the human IL-1 receptor antagonist (IL1-Ra) that inhibits IL-1α and IL-1β binding to the IL-1 receptor type 1. As inflammation comprises BBB dysfunction, the inhibition of IL-1 as proposed is a strategy enabling cerebrovascular protection ([@B88], [@B89]; [@B169]; [@B60]). Recent strategies include the development of IL-1Ra molecules fused with a cell-penetrating peptide to enhance brain access ([@B178]). After transient middle cerebral artery occlusion in rats, IL-1Ra-PEP reduced neuro-inflammation and ischemia ([@B178]). The fourth option is IPW-5371, a small molecule blocking the transforming growth factor β receptor (TGFβR) signaling. In a recent study ([@B144]), IPW reduced hyperexcitability in a mouse model, protecting BBB functions. The activated protein C (APC) therapeutic analog 3K3A-APC is a fifth option. This compound has BBB and neuro-protective properties ([@B162]; [@B181]; [@B173]; [@B150]; [@B72]; [@B83]) and it is in clinical trial for stroke treatment ([@B83]). Next is platelet-derived growth factor subunits BB (PDGF-BB). Following an acute vascular insult, activation of the PDGF receptor beta (PDGFRβ) by PDGF-BB is beneficial, protecting the endothelium--pericyte structures. The latter was reported in mouse models of status epilepticus ([@B8]) and cerebral ischemia ([@B92]). Conversely, in chronic disease settings (e.g., AD, epilepsy, etc.), activation of PDGFRβ may participate to inflammation ([@B137]; [@B62]). Under this circumstance, blocking PDGFRβ signaling by using the tyrosine kinase inhibitor Imatinib could represent an anti-inflammatory strategy ([@B137]; [@B62]). In general, reducing PDGFRβ signaling could lead to contrasting effects, e.g., pericyte deficiency and BBB breakdown ([@B15]; [@B29]; [@B9]; [@B61]; [@B103]; [@B109]) or anti-inflammatory ([@B137]; [@B62]), depending on disease stage (acute vs. chronic). Another option, Dexamethasone, is a glucocorticoid effective in the formation and maintenance of endothelial tight junctions ([@B51]; [@B107]). Dexamethasone was proposed to decrease the expression of the Jumonji Domain Containing 3 gene (JMJD3) and metallo-proteinases (MMP-2, MMP-3, and MMP-9). Finally, there is the vascular endothelial growth factor (VEGF). Amyloid accumulation is associated with endothelial apoptosis ([@B132]) in Alzheimer's patients as well as in mouse models. In AD mice, VEGF administration rescued memory deficits by preventing Aβ-induced vascular apoptosis ([@B132]). See [Table 2](#T2){ref-type="table"} for complete drug listing, mechanisms and bibliography.

###### 

Available molecules exerting BBB repairing and anti-inflammatory effects.

                           Category                                       Mechanism(s) of action                                                                    Reported effects                                                                *In vivo* /*in vitro* models         Clinical trials                                                                                                                          References
  ------------------------ ---------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Losartan                 Antihypertensive                               Angiotensin II antagonist                                                                 Improves barrier function                                                       Rats                                 Antihypertensive drug                                                                                                                    [@B69]; [@B57]; [@B50]
  Ripamycin                Immunosuppressant                              mTOR antagonist                                                                           Improves barrier function, promotes claudin-5                                   Mice                                 Prevention of transplant rejection                                                                                                       [@B168]
  Anakinra                 lnterleukin-1 receptor antagonist              Human interleukin-1 receptor antagonist (IL-IRa)                                          Decreases inflammation                                                          Rats                                 Anti-inflammatory drug currently used against rheumatoid arthritis cryopyrin-associated periodic syndromes (CAPS) and Still's disease.   [@B60]; [@B168]
  IPW                      TGFβR1 kinase inhibitor                        Inhibition of TGFβR signaling                                                             Reduces brain hyperexcitability, indirect BBB repair                            Mice                                 NA                                                                                                                                       [@B144]
  3K3A-APC                 Activated protein C (APC)                      BACE-1 inhibition, activation of protease-activated receptor 1                            Cytoprotective properties, neovascularization, neurogenesis                     Mice                                 In clinical trial for ischemic stroke (RHAPSODY)                                                                                         [@B162]; [@B181]; [@B173]; [@B150]; [@B72]; [@B83]
  PDGF-BB                  PDGFRb agonist                                 Increased expression of p-Smad2/3                                                         Ameliorates BBB function                                                        *In vivo*                            NA                                                                                                                                       [@B8]
  Imatinib                 Kinase inhibitor                               Inhibition of PDGFR signaling                                                             anti-inflammatory?                                                              Mice                                 Precursor cell lymphoblastic leukemia--lymphoma, dermatofibrosarcoma                                                                     [@B155]; [@B62]
  Dexamethasone            Glucocorticoid                                 Decreased JMJD3 gene expression, suppression of MMP-2, MMP-3, and MMP-9 gene activation   Preserves tight junctions integrity                                             *In vitro* BBB model                 Inflammatory conditions                                                                                                                  [@B51]; [@B107]
  Annexin-A1 (ANXA1)       Glucocorticoid anti-inflammatory effector      Binding to FRP2 receptor, inhibition of phospholipase-2                                   Restores cell polarity, cytoskeleton integrity, and paracellular permeability   *In vitro* BBB model, Anxa−/− mice   NA                                                                                                                                       [@B27]; [@B127]; [@B185]
  VEGF                     Vascular endothelial growth factor             Prevention of Aβ-induced apoptosis                                                        Improves vascular functions                                                     Mice                                 NA                                                                                                                                       [@B132]
  Tetramethylpyrazine      Cardiovascular                                 Blocking JAK/STAT signaling                                                               Reduces BBB damage                                                              Rats                                 NA                                                                                                                                       [@B44]
  *S*-nitrosoglutathione   Nitric oxide donor                             Suppression of MMP-9 activity                                                             Prevents BBB damage                                                             Mice                                 NA                                                                                                                                       [@B3]
  Cannabidiol              Analgesic, anti-inflammatory, antineoplastic   Activation of PPARy and 5-HT~1A~ receptors                                                Prevents BBB damage                                                             *In vitro* BBB model                 NA                                                                                                                                       [@B49]

Perspectives and Challenges {#S7}
===========================

The importance of cerebrovascular dysfunction in neurodegenerative disorders is twofold: BBB damage is pathophysiological and it allows a diagnostic window, the latter by exploiting specific proteins that shed from the damaged or vascular wall cells to appear into accessible fluids, e.g., blood or CSF. For instance, by dosing soluble PDGFRβ in CSF and by using dynamic contrast-enhanced magnetic resonance imaging, a recent study demonstrated BBB breakdown as an early biomarker of human cognitive dysfunction ([@B102]; [@B108]).

Tackling the complex neurodegenerative puzzle requires a continuous sharpening of pharmacological tools. This is important because no efficacious disease-modifying strategy is available to meaningfully delay or prevent disease progression. The problematics here presented may stem from semantic habits as the term *neuro-* indicates, for most, neurons only. Revisiting nomenclature(s) may benefit, if not legitimize, holistic, and neurovascular approaches to CNS disorders since it is evident that considering neuronal circuits insulated from the influence of glio-vascular cells is excessively reductionist.
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